WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

AN OVERVIEW OF GENE THERAPY USED IN CANCER TREATMENT.

Waahid hassan[1], Kamalesh Mistry[2], Dhananjay Mistry[3], Md. Aftab Alam[4], Komal Maliwal[5], Neha Nahid[6]

[1]Research Scholar, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh 312901, Rajasthan, India. Wahidrather09@gmail.com

[2]Assistant Professor, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh 312901, Rajasthan, India. drkamaleshmistry@gmail.com

[3]Lecturer, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh 312901, Rajasthan, India. dhananjaymistry.in@gmail.com

[4]Lecturer, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh 312901, Rajasthan, India. aftabalamm20@gmail.com

[5]Lecturer, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh 312901, Rajasthan, India. Komalmaliwal1999@gmail.com

[6]Lecturer, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh 312901, Rajasthan, India. nehanahid9334@gmail.com

Waahid hassan, Research Scholar, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh 312901, Rajasthan, India. wahidrather09@gmail.com

ABSTRACT:

Gene therapy is becoming an increasingly important tool in the fight against cancer, allowing scientists and clinicians to directly alter the genetic material in cancer cells or enhance the body's immune response. This review explores the basic principles behind gene therapy, the different methods of delivering therapeutic genes, and recent clinical developments in the field. Both viral and non-viral delivery systems are discussed, along with the role of newer gene- editing techniques like CRISPR/Cas9. As more therapies move through clinical trials and receive approval, gene therapy is gaining ground as a powerful complement—or even an alternative—to traditional cancer treatments. Still, important challenges remain, including the potential for side effects, unintended changes to DNA, and broader ethical questions that need to be addressed before widespread adoption can occur.

Keywords: gene therapy, cancer, CRISPR, gene editing, viral vectors, non-viral vectors, tumor suppression, cancer immunotherapy, targeted treatment, clinical trials.

Introduction:

Despite notable advancements in modern medicine, cancer remains one of the most common and deadly diseases worldwide. Treatments such as chemotherapy, radiation therapy, and targeted drugs have improved survival rates, but they often come with significant limitations, especially when it comes to targeting cancer cells without harming healthy ones. This lack of precision can lead to serious side effects and reduced quality of life for patients. In recent years, gene therapy has emerged as a promising alternative. By modifying the genetic material inside a patient's cells, it opens up new possibilities for treating and potentially curing cancer at its roots. Although gene therapy was first developed for rare genetic disorders, recent breakthroughs in molecular biology and gene-editing technologies have expanded its potential, making it a powerful tool in the fight against complex diseases like cancer.

Mechanisms of Gene Therapy in Cancer:

Gene therapy uses a range of strategies to tackle cancer at the genetic level, each tailored to disrupt the disease's progression in a unique way.

1.1 Gene Addition Therapy

This approach involves inserting healthy genes into cancer cells to restore functions that may have been lost or damaged. For instance, reintroducing a working version of the *p53* gene—often referred to as the "guardian of the genome"—can help restart the cell's natural self-destruct process (apoptosis) in tumors where this gene has stopped working.

1.2 Gene Silencing

Sometimes, cancer is driven by genes that are too active. In these cases, gene therapy aims to dial down or switch off those problematic genes. Techniques like RNA interference (RNAi) or antisense oligonucleotides are used to block the production of proteins that encourage tumor growth, essentially quieting the genetic signals that fuel the disease.

1.3 Suicide Gene Therapy

This technique turns cancer cells into agents of their own destruction. Genes are introduced that enable these cells to convert a harmless drug into a toxic one, but only within the tumor. A common example is the use of the HSV-tk gene from the herpes virus alongside ganciclovir, which kills only the modified cancer cells, sparing healthy tissues.

1.4 Immunomodulatory Gene Therapy

Rather than targeting the cancer directly, this method strengthens the body's own defenses. It involves modifying immune cells or introducing genes that produce immune-boosting substances like interleukin-2 (IL-2). Another powerful example is the development of CAR-T cells —T cells that are genetically equipped with chimeric antigen receptors, enabling them to seek out and destroy cancer more effectively.

Vectors for Gene Delivery:

In gene therapy, getting therapeutic genes into the right cells is essential, and various methods, called vectors, are used to accomplish this. These vectors fall into three main categories: viral, non-viral, and physical methods. Each type has its own set of advantages and challenges.

1.5 Viral Vectors

Viruses have evolved to efficiently deliver genetic material into host cells, making them ideal tools for gene therapy.

- Adenoviruses are particularly effective because they can transfer genes into both dividing and non-dividing cells, which makes them useful in a variety of applications.
- Retroviruses and lentiviruses integrate their genetic content directly into the host's DNA, ensuring that the introduced genes persist over time.
- Adeno-associated viruses (AAVs) are becoming more popular due to their relatively low immunogenicity, meaning they cause fewer immune responses, making them a safer option.

1.6 Non-viral Vectors

These include synthetic materials like liposomes, nanoparticles, and even unmodified DNA. While these methods are typically less efficient than viral vectors, they are much easier to produce and have fewer risks, which makes them appealing for certain situations, particularly when safety is a concern.

1.7 Physical Methods

In addition to viral and non-viral vectors, physical techniques can also be used to get genes into cells. Methods like electroporation (where cells are exposed to electrical pulses), gene guns (which shoot DNA-coated particles into cells), and ultrasound (which uses sound waves to aid gene uptake) provide alternative ways of delivering genetic material. These methods can be especially useful when you want to bypass using viruses or synthetic carriers altogether.

Gene Editing Technologies:

CRISPR/Cas9 has revolutionized the field of gene therapy, enabling highly accurate and efficient modifications to the genome. In cancer treatment, CRISPR is being used in a variety of ways, such as:

- Turning off oncogenes to stop the growth of tumors
- Enhancing the precision of T cell receptors, allowing them to better target cancer cells
- Fixing mutations in tumor suppressor genes, effectively restoring their normal protective function

While CRISPR has garnered most of the attention, other gene-editing technologies like zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) have also been studied. However, CRISPR has become the go-to method due to its simplicity, flexibility, and ability to target multiple genes at once.

Clinical Applications in Oncology:

Gene therapy is making significant strides in the fight against cancer, with various therapies progressing through clinical trials and some already achieving impressive results:

1.8 Leukemias and Lymphomas

One of the most remarkable successes of gene therapy has been in treating blood cancers, especially through CAR-T cell therapy. This approach involves modifying a patient's T cells to target the CD19 protein on B-cell tumors. Therapies like tisagenlecleucel have demonstrated impressive outcomes and have earned FDA approval for certain B-cell-related cancers.

1.9 Solid Tumors

While gene therapies for solid tumors are still largely in the research and experimental stages, there are several promising avenues. For instance, p53 gene therapy is being investigated for head and neck cancers, and suicide gene therapy is being tested for glioblastoma, a particularly aggressive type of brain cancer.

1.10 Oncolytic Virus Therapy

Oncolytic viruses are a fascinating area of research, where viruses are engineered to specifically infect and destroy cancer cells. One such therapy, Talimogene laherparepvec (T-VEC), which uses a modified herpes simplex virus, has already been approved by the FDA for melanoma treatment, offering new hope for patients with advanced skin cancer.

Challenges and Limitations:

Although gene therapy has made great strides, there are still several challenges that need to be overcome:

- Immune Response: Viral vectors, which are often used to deliver genes, can trigger strong immune reactions. This can reduce the effectiveness of the treatment or even cause adverse effects.
- Off-target Effects: While gene editing technologies are highly precise, they can sometimes cause unintended genetic changes, which may lead to complications.
- Tumor Heterogeneity: Cancer cells within a single tumor, or across different tumors, can vary greatly in their genetic makeup. This makes it difficult to develop therapies that effectively target all cancerous cells.
- Ethical and Regulatory Concerns: The potential for germline editing and the long-term safety of gene therapies continue to raise ethical questions and regulatory challenges, as these therapies could have far-reaching implications.

Future Perspectives:

Looking ahead, several promising trends are emerging in the field of gene therapy for cancer treatment:

- Personalized Gene Therapy: Customizing gene therapies based on the unique genetic makeup of a patient's tumor, leading to more precise and effective treatments.
- Combination Therapies: Combining gene therapy with other approaches like chemotherapy or immunotherapy to improve overall treatment effectiveness.
- Synthetic Biology: Leveraging synthetic biology to create engineered cells that can be programmed to specifically target and eliminate cancer cells.

As these technologies continue to develop and safety concerns are addressed, gene therapy could shift from being an experimental approach to becoming a standard treatment option in cancer care.

Conclusion:

Gene therapy is revolutionizing the way we approach cancer treatment, offering new possibilities for treatments that are both highly targeted and personalized. With continued advancements in gene delivery systems and editing technologies, and as clinical trials progress, gene therapy has the potential to significantly reshape cancer care. However, to fully realize its potential, it will be crucial to address current challenges through collaborative efforts across various fields.

REFERENCES:

1. Cavazzana, M., et al. (2019). A forward-looking overview of gene therapy advancements. Nature Reviews Drug Discovery, 18(6), 405–423.
2. Maude, S. L., et al. (2014). Achieving long-term remission in leukemia using CAR T cell therapy. New England Journal of Medicine, 371(16), 1507–1517.
3. Ginn, S. L., et al. (2018). Global landscape and trends in gene therapy trials up to 2017. The Journal of Gene Medicine, 20(5), e3015.
4. Liu, X., et al. (2020). The role of CRISPR/Cas9 in cancer treatment: present hurdles and future directions. Frontiers in Oncology, 10, 604.
5. Russell, S. J., et al. (2012). Harnessing viruses to fight cancer: a review of oncolytic virotherapy. Nature Biotechnology, 30(7), 658–670.
6. Naldini, L. (2015). The renewed prominence of gene therapy in modern medicine.
7. Nature, 526(7573), 351–360.
8. Fesnak, A. D., et al. (2016). The potential and complexity of engineered T cells in cancer immunotherapy. Nature Reviews Cancer, 16(9), 566–581.

9. Wang, D., et al. (2019). Exploring adeno-associated viruses as gene delivery vehicles. Nature Reviews Drug Discovery, 18(5), 358–378.
10. Sadelain, M., et al. (2013). Designing effective CARs: foundational concepts and considerations. Cancer Discovery, 3(4), 388–398.
11. Yu, W., et al. (2021). Innovations in non-viral systems for delivering genes in cancer therapy. Biomaterials Science, 9(3), 674–689.